Home EEG monitoring for fenfluramine treatment in dravet and lgs
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests whether a reduced, home-based EEG monitoring device can help doctors safely adjust the dose of fenfluramine, a treatment for seizures in Dravet syndrome and Lennox-Gastaut syndrome. Participation may help find the right dose with fewer hospital visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have a confirmed diagnosis of Dravet syndrome or Lennox-Gastaut syndrome (LGS) and be a candidate for fenfluramine treatment.
- Fenfluramine must be newly prescribed (not previously taken).
- You or a caregiver must be able to track seizures regularly, for example in a diary or app.
- The patient must be at least 4 years old.
- You cannot have a pacemaker, defibrillator, or other implanted device.
- You cannot be taking stiripentol or certain other medications (like SSRIs or MAO inhibitors) that could interact with fenfluramine.
- You must have a history of motor seizures (not just non-motor seizures) and no significant heart or blood vessel disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how brain wave patterns change when children and young adults with Lennox-Gastaut Syndrome (a severe seizure disorder) take fenfluramine, a medication that helps reduce drop seizures. Researchers will use EEG (brain wave recordings) to understand how this treatment affects the brain.
This trial tests the safety of a medicine called fenfluramine for children under 2 years old with Dravet syndrome. It aims to see if fenfluramine can help control seizures in very young children.
This trial tests a new type of brain stimulation (adaptive deep brain stimulation) that adjusts in real time to stop seizures in children with Lennox-Gastaut syndrome. It's for children who haven't gotten enough help from medications and have frequent drop seizures.
This study tests a brain implant that delivers electrical stimulation during sleep to reduce seizures in people with Lennox-Gastaut syndrome. It aims to improve seizure control and sleep quality.
This study tests whether the drug fenfluramine can reduce the risk of sudden unexpected death (SUDEP) in people with Dravet syndrome who have generalized convulsive seizures. It aims to see if a lower dose can still prevent seizures and protect the heart and breathing during a seizure.
This study tests using a small, home-based EEG device to monitor brain activity over several weeks in people with hard-to-control seizures, rare epilepsies, or developmental and epileptic encephalopathies. The goal is to see if this method can better track seizures and improve care.
Hear when a new Lennox Gastaut Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.